Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $4.77M fell 17.7% year over year, ahead of the -22.5% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 4.6% from the prior quarter. Over 3 fiscal years it compounded at -9.9% a year.
Context
- Selling, general & admin amounted to 184.6% of revenue in FY2025, down 225.7 pp from a year earlier.
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 2 analysts of $37.18M (+65.9%) for the fiscal year ending Dec 2026, a step up from the -22.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.77M-4.6% QoQ
- Last fiscal yearDec 2025
- $22.41M-22.0% YoY
- LTMMar 2026
- $21.38M-22.5% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 22.41M USD
- Year-over-year change
- -22.0%
- 4-year CAGR
- -4.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.41M | -22.0% |
| FY2024 | 2024-12-31 | 28.72M | -0.6% |
| FY2023 | 2023-12-31 | 28.88M | -5.8% |
| FY2022 | 2022-12-31 | 30.65M | +13.7% |
| FY2021 | 2021-12-31 | 26.96M | — |
Selling, General & Admin vs competitors
How PRLD compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -22.5% is the 10th highest of 11, against a peer median of +4.8%.
- Selling, general & admin amounts to 127.9% of revenue for PRLD, versus a peer median of 234.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.7B USD | +29505.3% | +3.5% | — | |
| FY2025 | €53.89M EUR | +215.2% | +51.5% | 1202.1% | |
| LTM Mar 2026 | $38.28M USD | -25.4% | -1.1% | 55.3% | |
| LTM Mar 2026 | $36.25M USD | -1.5% | -0.1% | 323.5% | |
| LTM Mar 2026 | $26.99M USD | +11.1% | +24.6% | 82.5% | |
| LTM Mar 2026 | $26.89M USD | -3.6% | -3.6% | 95.3% | |
| LTM Mar 2026 | $24.19M USD | +23.5% | +3.4% | 41000.0% | |
| LTM Mar 2026 | $23.71M USD | -4.5% | +3.4% | 10537.3% | |
| LTM Mar 2026 | $21.38M USD | -22.5% | -9.9% | 127.9% | |
| LTM Mar 2026 | $20.02M USD | -13.1% | -15.9% | 144.4% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $17.83M USD | +52.6% | +62.5% | — |
| Peer median (excluding PRLD) | — | +4.8% | +3.4% | 234.0% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7M | 12.14M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.71M |
| Gross Profit | 0 | 0 | 0 | 7M | 10.43M |
| Gross Margin | — | — | — | 100.0% | 85.9% |
| Research & Development | 86.78M | 92.89M | 103.39M | 118M | 94.3M |
| Selling, General & Admin | 26.96M | 30.65M | 28.88M | 28.72M | 22.41M |
| Operating Expenses | 113.74M | 123.54M | 132.28M | 146.71M | 115M |
| Depreciation & Amortization | 915K | 1.32M | 1.17M | 1.77M | 1.71M |
| EBITDA | (110.78M) | (114.11M) | (120.66M) | (125.4M) | (97.79M) |
| EBITDA Margin | — | — | — | -1791.4% | -805.5% |
| Operating Income | (113.74M) | (123.54M) | (132.28M) | (139.71M) | (104.57M) |
| Operating Margin | — | — | — | -1995.9% | -861.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 2.04M | 8.1M | 10.44M | 12.54M | 5.07M |
| Income Before Tax | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Pre-Tax Margin | — | — | — | -1816.8% | -819.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Net Margin | — | — | — | -1816.8% | -819.6% |
| EPS (Basic) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| EPS (Diluted) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| Weighted Avg Shares | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
| Weighted Avg Shares (Diluted) | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.